Background. To investigate whether altered cross-bridge kinetics contribute to the contractile abnormalities observed in heart failure, we determined the mechanical properties of cardiac muscles from control and myopathic hearts.
D ilated cardiomyopathy is characterized by impaired contractile function and dilation of one or both ventricles. The cellular mechanisms underlying the systolic and diastolic dysfunction in heart failure are being slowly unraveled.1-6 Recent experiments on isolated human myocardium have revealed that myopathic hearts have altered metabolic and structural properties.' When compared with normal myocardium, myopathic hearts show differences in rates of tension development,2 creatine kinase activity,3 sarcolemmal receptors,45 and cAMP content.6'7 These dif-between control and myopathic hearts. 8, 9 Additional results revealed that the dysfunction underlying diseased myocardium is not due to reduced calcium release from the sarcoplasmic reticulum.10'11 It has been proposed that subcellular alterations in the number of cross-bridge interactions may result in myocardial failure.12 Because changes in cross-bridge kinetics and number of cycling cross-bridges could affect contractile function, we became interested in examining the regulation of cross-bridge dynamics in heart failure. We therefore used two direct techniques to measure the cross-bridge cycling rate: 1) unloaded velocity of shortening and 2) dynamic stiffness calculated from the ratio of force response to length perturbation amplitude. Methods
Muscle Preparation
Trabeculae carneae were obtained from the right ventricles of hearts of patients with end-stage heart failure undergoing heart transplantation (n=6) as described earlier.2'8-10 All patients from this group were diagnosed as having idiopathic dilated cardiomyopathy characterized by an increase in ventricular size and impaired ventricular function without angiographic evidence of significant coronary artery disease (no lesions resulting in obstruction of >50%), valve disease, insulin-dependent diabetes, congenital malformations, hemochromatosis, amyloidosis, or infections. The mean age of the patients was 41.3±2.7 years. None of the patients had a reported family history of cardiomyopathy, a personal history of alcoholism, or human immunodeficiency virus infection. On endomyocardial biopsy, there was no evidence of active myocarditis among these patients. On gross inspection, the hearts were markedly enlarged, with severe four-chamber dilation and an average weight of 730.4±24.5 g. Histologically, all patients had generalized cellular hypertrophy and diffuse interstitial fibrosis measured by light microscopy. None of the patients were receiving p-blockers or Ca'+ blockers before transplant. The mean ejection fraction measured by two-dimensional echocardiography was 17±1%. Areas containing large amounts of fibrosis were avoided during muscle selection. Control hearts (n=5) were obtained from brain-dead organ donors (mean age, 35.4±2.3 years), without known cardiac disease who died from trauma. On gross inspection, the control hearts were normal without areas of scarring or thinning and with an average weight of 210±23 g. Histologically, cellular dimensions were within normal limits with no evidence of hypertrophy or extensive fibrosis. All experimental protocols were reviewed and approved by an internal review board.
After removal from the chest, the left and right ventricles were opened surgically and placed into an oxygenated physiological solution (see composition below). The tissue was then transported to our laboratory, arriving 20 minutes to 2 hours after removal from the thoracic cavity for both control and myopathic hearts. Suitable thin trabeculae carneae were removed and studied immediately. Muscle dimensions were measured by a light microscope (x 10) equipped with a calibrated eyepiece. Two measurements of diameters were assessed at two different muscle orientations perpendicular to each other, and the average of these two measurements was taken as muscle diameter. Trabeculae diameters were 455±60 gm (n=5) from control hearts and 416±75 ,um (n=6) from myopathic hearts, corresponding to cross-sectional areas <0.5 mm2. The muscle lengths measured at L,,. (defined below) were 5.05±0.34 mm (n=5) from control hearts and 5.33±0.22 mm (n=6) from myopathic hearts. There were no physiological differences in muscle parameters by Student's t test. The muscles were clamped at one end of a muscle holder and attached at the other end to a Servo-controlled electromagnetic lever system (Cambridge 300H, Watertown, Mass.). The signals from the force and displacement transducers were displayed simultaneously on a Gould diode array recorder. The muscles were superfused with a bicarbonate-buffered oxygenated solution with the following composition (mM): NaCI 120, KCl 5.9, NaHCO3 25, NaH2P04 1.2, MgCl2 1.2, CaCl2 2.5, dextrose 11.5, bubbled with 95% 0°a nd 5% CO2, pH 7.4. Muscles were stimulated with a square wave pulse of 5-msec duration at threshold voltage at a frequency of 0.33 Hz. The muscle length was then adjusted to L,.,,, a length at which maximal active twitch force (total force minus diastolic force) was achieved.
Skinning Procedure
After setting L,,. in the intact state, the muscles were chemically skinned by exposure to a solution containing saponin 250 ,ug/ml, K2ATP 5 mM, MgCl2 7 mM, EGTA (ethyleneglycol-bis-N,N,N,N'-tetraacetic acid) 5 , and pH at a constant ionic strength were calculated using the program described by Fabiato.13 The solutions were prepared at a temperature of 22°C with a pMg of 2.5, pMgATP of 2.5, an EGTA concentration of 10 mM, an ionic strength of 0.16 M, and a pH of 7.1 adjusted using 30 mM TES. The solutions also contained 12 mM phosphocreatine and 15 units/ml creatine phosphokinase. All stock solutions were prepared in plasticware: 5 mM K2CaEGTA was prepared with CaCO3, EGTA, and KOH at 80°C; 5 mM K2EGTA was prepared with EGTA and KOH. Creatine phosphate and creatine phosphokinase were added immediately before the experiment. The relaxation solution had a pCa >8.0, whereas the maximal activation solution had a pCa of 4.0.
Unloaded Shortening As described above, the muscles were skinned, maximally activated, and then quickly released from the end attached to the galvanometer (in less than 1 msec), causing a rapid fall in tension. The time At was measured from the onset of release to the point at which the force started to redevelop. The data relating amplitude AL and duration At of unloaded shortening after various amplitudes of quick releases were fitted with a regression line using the least-squares method as described by Edman.14 
Dynamic Stiffness
Once the skinned muscles achieved maximal force at a pCa of 4.0, they were subjected to sinusoidal oscillations from the end of the muscle attached to the galvanometer at 20 discrete frequencies from 0.01 Hz to 100 Hz at a fixed amplitude of 1% L,, peak to peak.
Both AL and AF were measured throughout these frequencies. Dynamic stiffness of the muscle was defined as AF/AL and then normalized to the value that would be obtained if each muscle had a length of 5 mm and a cross-sectional area of 0.5 Mm2m. Dynamic stiffness was then plotted as a function of frequency of oscillations.1516 Phase shift between force and muscle length was measured by the time difference between the peaks of force and muscle length. We generated the dynamic stiffness spectrum using whole muscle length, which generally includes damaged end regions.
Statistical Analysis
Results are presented as mean+SEM. Statistical significance in the comparisons made between frequencies of minimum stiffness, velocities of unloaded shortening, and stiffness measurements between control and myopathic muscles were determined by the Student's t test. Results
Skinned Fibers
The activation range for both control and myopathic skinned muscles was between 10`7 M and 10`4 M, with both groups being maximally activated at a pCa <4.5. The force development saturated at a pCa of 4.5 and remained maximal at a pCa of 4.0. As shown in Figure  1 , there were no differences in Ca2+ sensitivity or cooperativity (steepness of the force-[Ca21] relation, reflecting long-range associations among cycling crossbridges) between skinned trabeculae from control and myopathic hearts. Maximal force measured at a pCa of 4.0 was 0.35±0.06 g/mm2 for control and 0.33±0.08 g/mm2 for myopathic muscles.
Velocity of Unloaded Shortening
Control and myopathic muscles were maximally activated at a pCa of 4.0 and then quickly released to different lengths as shown in Figure 2 . The release caused a rapid fall in tension to zero. The tension remained at zero until force redeveloped with an exponential rise and then reached a plateau. The releases started at the same muscle length, Ll,., and the redevelopment of tension occurred at different lengths, depending on the amplitude of the release (the smallest one being 5%). The muscles were then restretched to L,. There was a linear relation between AL and At, as shown in Figure 2 . The slope of the line has been shown to provide a measure of the velocity of unloaded shortening.14 In control muscles, the unloaded shortening velocity V0 was 0.72±0.09 L,/ajsec, whereas in myopathic muscles, V0 was 0.41±0.06 Lmax/sec (p<O.OOS). The y-intercept of the fitted line is a measure of the series elastic element of the muscles. As noted in Figure 2 , myopathic muscles had series elasticities that were similar to control muscles (0.04+ 0.01 L.. versus 0.03+0.01 Ln,, respectively).
Dynamic Stiffness
As length was oscillated sinusoidally, the force outputs were sinusoidal in both control and myopathic muscles, as shown in Figure 3 . At low frequencies of oscillations, the amplitude of force oscillation was constant in both control and myopathic muscles. As the frequency increased, the amplitude of force decreased and reached a minimum at about 0.78±0.06 Hz (n=5) for control muscles and 0.42±0.07 Hz (n=6) for myopathic muscles (p<0.01). This frequency has been termed frequency of minimum stiffness (fm,u). Further increases in the frequency of oscillation resulted in an increase in stiffness that reached a plateau >30 Hz. Representative frequency spectra of the stiffness measurements of normal and myopathic skinned trabeculae are shown in Figure 4A . Table 1 depicts the stiffness measurements at low, minimum, and high frequencies (KOw K~, and K,igb, respectively). The stiffness measurements were significantly higher in myopathic muscles compared with control muscles at low frequencies (<0.2 Hz). The values for minimum and high stiffnesses were not different between control and myopathic muscles. The phase shift between force and muscle length also showed a strong frequency dependence, as seen in Figure 4B . The phase shift was close to zero at low frequencies. Above the frequency of minimum stiffness, the phase shift became abruptly positive, reaching a maximal value of -80°. At higher frequencies, the phase shift gradually decreased toward zero.
The stiffness spectra of skinned trabeculae at a pCa of 8.0 increased slightly with increasing frequency. Myopathic muscles had higher resting stiffness than control muscles throughout all frequencies.
Force-High-Frequency Stiffness Relation
To examine whether the stiffness at high frequencies is governed by the active level of force, we related the stiffness at 100 Hz versus the mean level of force at 100 Hz. We combined the data points for both control and myopathic muscles because there were no statistical differences between the coefficients of linear regression. Figure 5 shows the correlation of the combined data between force and high-frequency stiffness to be KYhig=16.31f+0.14, where f is force developed. This linear relation shows that the high-frequency stiffness is nearly proportional to mean force, suggesting that the elasticity measured at high frequencies resides within actively cycling cross-bridges. From this correlation, the required size for a sudden shortening step that would bring force to zero can be calculated as activated the myofilaments in skinned fiber preparations. Other methods have been developed to obtain steady activation in intact cardiac muscle including barium contracture, which has been used by many investigators to measure cross-bridge cycling rate15-21 and recently in isolated, perfused working hearts. 22 We have also used tetanizations of human myocardium to obtain steady-state activation.8 However, we elected to use membrane-free preparations because we were interested in examining only the contractile proteins without having to address the possibilities that there may be differential effects of muscle length stretches on the sarcoplasmic reticulum, the sarcolemma, and receptors resulting in the observed differences. We used two techniques to investigate the crossbridge cycling rate in control and myopathic hearts. The traditional method of assessing cross-bridge cycling rate has been the maximal unloaded shortening velocity during contraction developed by Edman.'4 This technique has been extensively used in skeletal muscles and has become widely accepted for use in cardiac muscles. It measures the velocity at which the cross-bridges cycle to take up the slack induced by a length change under zero load.
Several investigators have interpreted the time course of force transients in response to rapid, small-amplitude length changes applied to isometrically contracting cardiac muscle in terms of the kinetics of the active inter-action of myosin with actin.15-2l23,24 More specifically, the frequency of minimum stiffness reflects the frequency at which resonance exists between the mechanical cycle of the muscle during activation and the mechanical frequency imposed on the muscle. Based on the complex stiffness spectra of activated cardiac and skeletal muscle, several investigators have constructed specific mathematical models in which the frequency of minimum stiffness reflects the mean cycling rate.1516202324 Furthermore, it has been shown recently that f,in is similar in skinned myocardium and intact myocardium. 25 The view that the frequency of minimum stiffness is an indicator of intrinsic contractile rate has been supported by experiments that demonstrate this frequency to be independent of muscle length and degree of activation but to be strongly dependent on temperature,15'16 MgATP concentrations, myosin isozyme composition,16,23 age,'6 and the presence of cAMP-varying compounds.l920, 26 It is important to note that the information provided by the two techniques are different in terms of steps in the cross-bridge cycle. Vo is measured under zero load starting with all cross-bridges in the detached state and reflecting the speed with which the cross-bridges, through multiple cycles, produce shortening and is limited by the rate of cross-bridge detachment.'4 The frequency of minimum stiffness is derived under isometric conditions and is an index of the mean cross-bridge cycling rate. Both measurements are thought to be To the extent that fmin and V0 represent cross-bridge cycling rate, our findings show that the cycling rate is slowed in failing hearts.
We found that the series elasticity was higher with Edman's slack test when compared with the series elasticity obtained with high-frequency stiffness measurements (3% versus 1%). One explanation is that with the slack test, chord stiffness is actually measured, and viscous properties of the damaged ends' series elasticity predominate, whereas the series elasticity observed with the dynamic stiffness spectra are the instantaneous stiffness of elements in series and parallel built into the sarcomeres. Nevertheless, the series elasticity does not affect V0 or frequency of minimum stiffness measurements. 27 Another consideration in our measurements was control of sarcomere length because it can influence calcium sensitivity and velocity of shortening.28-30 Although we did not measure sarcomere length in our preparations, the muscles were all activated at L.,,. In preparations such as ours, the central (healthy) portion of the muscle preparation shortens during a twitch while the ends of the excised muscles are held constant. Depending on the amount of damage in the end regions, shortening in the middle portion can be as much as 15% of the total muscle length.31 This leads to shortening of the sarcomeres in the middle portion while stretching the sarcomeres in the end region. The greater the amount of damage in the end region, the higher the expected series elasticity derived from the Edman slack test. However, in our preparations, series elasticity measured with the Edman slack test did not exceed 4% of L,,, and there were no differences between control and myopathic muscles, which argues against differential amounts of damaged ends accounting for changes in the unloaded velocity of shortening.
Cross-Bridge Cycling Rate and Contractile Proteins
In human dilated cardiomyopathy, changes in the functional properties of the myofilaments have been reported that may explain altered cross-bridge cycling rate.89,32-35 Shortening velocity and ATPase activity in cardiac muscle have been shown to correlate with myosin isoforms V1, V2, and V3.21,36 The ratio of these isomyosins varies according to the maturational and pathological state of animals, with V, being associated with higher ATPase activity and shortening velocity (hyperthyroid, fetal) and V3 being associated with lower ATPase activity and shortening velocity (hypothyroid, hypertrophy, adult). 21, 36, 37, 38 In humans, however, the V3 isoform predominates, and in dilated and hypertrophic cardiomyopathy, no consistent change in isozyme pattern has been found. 37, 38 A recent report by Margossian et a139 showed a decrease in the content of myosin light chain kinase 2 (LC2) in ventricles from patients with dilated cardiomyopathy. In cardiac muscle, LC2 modifies the actomyosin reaction. It has been shown that LC2 removal in skinned myocardial preparations results in 1) an increase in force production at submaximal [Ca21], 2) a leftward shift of the force-[Ca2 ] relation, 3) no change in maximal Ca2'-activated force, and 4) a decrease in unloaded velocity of shortening.40 Although no significant difference in the sensitivity of the myofilaments to Ca 2 was observed in our preparations, we did find, consistent with a loss of LC2, diminished velocity of unloaded shortening and cross-bridge cycling rate, an unchanged maximal Ca 2+-activated force, and increased resting stiffness in cardiomyopathy. Furthermore, myofibrillar MgATPase activity has been shown to be reduced in myopathic ventricles41-43; more specifically, our myopathic preparations demonstrated a decrease in myosin ATPase activity by -25% when compared with normal preparations (unpublished results).
Thin filament regulation and structure also have been shown to be altered in human cardiomyopathy.O8933, 35 (TnT2), a fetal isoform that in mammalian myocardium confers a greater sensitivity of the myofilaments to Ca2' and a decrease in maximum myofibrillar ATPase activity. [42] [43] [44] [45] It was argued that the increase in TnT2 in failing human myocardium may play a role in the regulation of force development and calcium activation.43 However, TnT2 was only :15% of the TnT population in the myopathic hearts, making it unlikely that the significant decrease in myofibrillar ATPase observed in failing hearts can be entirely accounted for by TnT2. The fact that in this study we did not find any changes in myofilament sensitivity to Ca2' also argues against a major role of TnT2.
Physiological Implications A decreased cross-bridge cycling rate allows longer interaction periods between actin and myosin, resulting in greater force development. 46 Therefore, in diseased human myocardium, the slower cross-bridge cycling rate would seem to compensate for the decrease in myofibrillar protein content. This would explain in part the finding of similar contractile performance reported in The slowing of cross-bridge cycling rate does not seem to be specific only to human heart failure. Many animal models of hypertrophy have been associated as well with a decrease in shortening velocity.49-52 Idiopathic dilated cardiomyopathy in humans is a disease of unknown cause and may be the result of a variety of insults. The natural history of this condition is not well defined because the presenting symptom of affected patients is usually overt heart failure, the end-stage of the disease. For this reason, it is not clear whether the progression of the disease includes a stage of compensated myocardial hypertrophy that resembles that of most animal models. The decrease in cross-bridge cycling rate seems to reflect an adaptation to both hypertrophy and heart failure.
High-Frequency Stiffness and Maximal Ca2+-Activated Force
Recent experiments in failing hearts have suggested that a reduced number of available cycling cross-bridges are responsible for contractile failure in myopathic hearts. 12 Hasenfuss et a112 found that tension-dependent heat, which is thought to reflect the number of force-producing cross-bridges, was reduced by 61% in failing hearts. We measured the stiffness at high frequencies of oscillations, which is governed by the tension generated per cross-bridge. 15, 16, 24 In our experiments, there were no differences in high-frequency stiffness for control and myopathic muscles. This does not necessarily translate into a similar number of attached cross-bridges, because if the cross-bridges are stiffer in myopathic muscles, high-frequency stiffness would be the same even with a reduced number of cross-bridges in myopathic tissue. The instantaneous stiffness measured at high frequencies reflects both the number of attached cross-bridges in the force-producing and non-force producing state. However, we found the same maximal Ca2'-activated force in control and myopathic muscles, which argues that indeed the number of force-producing cross-bridges are probably similar in control and myopathic myocardium.
Conclusions
In the present study, we have unambiguously shown that the cross-bridge cycling rate determined by using two methods is slower in myopathic compared with control hearts. Furthermore, we showed that there are no differences in maximal Ca2' activation between control and myopathic muscles and that the number of force-producing cross-bridges is similar. These findings suggest that 1) the potential for force development is similar in normal and myopathic hearts and 2) there are changes at the level of the contractile proteins that result in reduced cross-bridge cycling rate and lowered energy requirement.
